Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Similar documents
Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or

Coronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)

Diabetes: HbA1c Poor Control (NQF 0059)

Childhood Immunization Status (NQF 0038)

Childhood Immunization Status (NQF 0038)

Measure Information Form

Weight Assessment and Counseling for Children and Adolescents (NQF 0024)

High Performance Network Quality Criteria for Designation

2017 CMS Web Interface

MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache

2017 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

Significance of Chronic Kidney Disease in 2015

Cardiac Rehabilitation Services

2017 CMS Web Interface

CLINICAL MEDICAL POLICY

2018 CMS Web Interface

2018 CMS Web Interface

2018 CMS Web Interface

Echocardiography Diagnostic Accuracy

Use of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol

2017 CMS Web Interface

2018 CMS Web Interface

2017 CMS Web Interface

2017 CMS Web Interface

BP Thresholds for Medical Review

2018 CMS Web Interface

Michigan Primary Care Transformation Project Performance Incentive Technical Manual

2018 CMS Web Interface

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers

Clinical Study Synopsis

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers

National Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)

2017 CMS Web Interface

NQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control

Solid Organ Transplant Benefits to Change for Texas Medicaid

Obesity/Morbid Obesity/BMI

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

LTCH QUALITY REPORTING PROGRAM

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

2018 CMS Web Interface

NPCR CLINICAL EDIT CHECKS

o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17

ICD-10-CM Coding Basics Chapter Specifics

COPD Outreach Program

Measure Specific Guidelines for Comprehensive Diabetes Care (CDC)

2018 CMS Web Interface

CDC Influenza Technical Key Points February 15, 2018

NIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO

Cognitive enhancers for the treatment of Alzheimer s disease

Trust Guideline for Urgent Brain Imaging and Management of Suspected Subarachnoid Haemorrhage

Technical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations

WARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES

2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)

AdvantEdge Healthcare Solutions: 2012 Physician Quality Reporting System (PQRS) Manual

Identification and Management of Hypertension. Definition of HTN

Do Not Cite. Draft for Work Group Review.

APPENDIX A Certification of Advanced Disease:

Pain Management Learning Plan

US Public Health Service Clinical Practice Guidelines for PrEP

Related Policies None

Emergency Department Performance Measures

NCT ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: PRIST_L_ Study Code: PRISTINAMYCIN Date: Generic drug name:

Swindon Joint Strategic Needs Assessment Bulletin

HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.

o Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient

ANDREW BRAUNSTEIN. o MIT (3 degrees Computers / Management) o 25 years building Clinical Systems. o 6 Patents in Clinical Technologies

Ischemic heart disease (angina/chest pain)

ALCAT FREQUENTLY ASKED QUESTIONS

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Hospital Performance Series

OTHER AND UNSPECIFIED DISORDERS

National Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes

CDC Influenza Division Key Points MMWR Updates February 20, 2014

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Lyme Disease Surveillance in North Carolina

Affects a large segment of health care community Tied to health outcomes Addresses clinical conditions of high prevalence, high costs, high risks

Heart Failure 6/29/2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Oral Surgery (Facial Pain) Service Specification

UNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Clinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

Medicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes

Rituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Annex III. Amendments to relevant sections of the Product Information

HEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8

Completing the NPA online Patient Safety Incident Report form: 2016

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

CDC Influenza Division Key Points November 7, 2014

QUALITY AND SAFETY MEASURES UPDATE January 2016

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

HOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM

Using Telin Mediplan to Support Patient s Medical Home

Drug Therapy Guidelines

Drug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)

Transcription:

Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December 31, 20xx Measure Steward Endrsed by Descriptin Measure scring Measure type Ratinale Clinical Recmmendatin Statement References American Medical Assciatin Physician Cnsrtium fr Perfrmance Imprvement Natinal Quality Frum Percentage f patients aged 18 years and lder with a diagnsis f heart failure and LVSD (LVEF < 40%) wh were prescribed ACE inhibitr r ARB therapy. Prprtin Prcess In the absence f cntraindicatins, ACE Inhibitrs r ARBs are recmmended fr all patients with symptms f heart failure and reduced left ventricular systlic functin, as measured by left ventricular ejectin fractin (LVEF). Bth drugs have been shwn t decrease mrtality and hspitalizatins. Heart Failure: Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD). Angitensin cnverting enzyme inhibitrs are recmmended fr all patients with current r prir symptms f HF and reduced LVEF, unless cntraindicated. (Class I Recmmendatin, Level f Evidence: A)(ACC/AHA) Angitensin II receptr blckers apprved fr the treatment f HF are recmmended in patients with current r prir symptms f HF and reduced LVEF wh are ACEI intlerant. (Class I Recmmendatin, Level f Evidence: A) (ACC/AHA) Angitensin II receptr blckers are reasnable t use as alternatives t ACEIs as first line therapy fr patients with mild t mderate HF and reduced LVEF, especially fr patients already taking ARBs fr ther indicatins (Class IIa Recmmendatin, Level f Evidence: A) (ACC/AHA). Definitins

Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Please refer t the spreadsheet fr this measure fr detail regarding data criteria and cde lists. Ppulatin criteria Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = Patient characteristic: birth date (age) >=18 years; Diagnsis active: heart failure ; OR: >=2 cunt(s) f: OR: Encunter: encunter utpatient ; OR: Encunter: encunter nursing facility ; OR: >=1 cunt(s) f: Encunter: encunter inpatient discharge ; All patients in the initial patient ppulatin; OR: Diagnstic study result: LVF assessment, result <40%; OR: Diagnstic study result: ejectin fractin, result <40%; OR: Medicatin rder: ACE inhibitr r ARB ; OR: Medicatin active: ACE inhibitr r ARB ; OR: Medicatin allergy: ACE inhibitr r ARB ; OR: Medicatin adverse event: ACE inhibitr r ARB ; OR: Medicatin intlerance: ACE inhibitr r ARB ; OR: Diagnsis active: pregnancy ; OR: Diagnsis active: deficiencies f circulating enzymes ; OR: Diagnsis active: disease f artic and mitral valves ; OR: Diagnsis active: nn rheumatic mitral (valve) disease ; OR: Diagnsis active: chrnic kidney disease with r withut hypertensin ; OR: Diagnsis active: hypertensive renal disease with renal failure ; OR: Diagnsis active: athersclersis f renal artery ; OR: Diagnsis active: renal failure and ESRD ; OR: Diagnsis active: acute renal failure ; OR: Diagnsis active: atresia and stensis f arta ; OR: Medicatin nt dne: medical reasn ; OR: Medicatin nt dne: patient reasn fr ACE inhibitr r ARB decline ;

OR: Medicatin nt dne: patient reasn ; OR: Medicatin nt dne: system reasn ; Data Criteria (QDS Data Elements) Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = "Patient characteristic: birth date using birth date cde list befre the measurement perid ; Diagnsis active: heart failure using heart failure cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Encunter: encunter utpatient using encunter utpatient cde list during the measurement perid ; Encunter: encunter nursing facility using encunter nursing facility cde list during the measurement perid ; Encunter: encunter inpatient discharge using encunter inpatient discharge cde list during the measurement perid ; All patients in the initial patient ppulatin; Diagnstic study result: LVF assessment using LVF assessment cde list befre Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnstic study result: ejectin fractin using ejectin fractin cde list befre Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin rder: ACE inhibitr r ARB using ACE inhibitr r ARB cde list during the measurement perid ; Medicatin active: ACE inhibitr r ARB using ACE inhibitr r ARB cde list during the measurement perid ; Medicatin allergy: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin adverse event: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin intlerance: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: pregnancy using pregnancy cde list gruping during Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: deficiencies f circulating enzymes using deficiencies f circulating enzymes cde list gruping befre r simultaneusly t Encunter: encunter

utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: disease f artic and mitral valves using disease f artic and mitral valves cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: nn rheumatic mitral (valve) disease using nnrheumatic mitral (valve) disease cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: chrnic kidney disease with and withut hypertensin using chrnic kidney disease with and withut hypertensin cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: hypertensive renal disease with renal failure using hypertensive renal disease with renal failure cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: athersclersis f renal artery using athersclersis f renal artery cde list cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: renal failure and ESRD using renal failure and ESRD cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: acute renal failure using acute renal failure cde list befre r simultaneusly t Encunter: utpatient OR Encunter: nursing facility OR Encunter: inpatient discharge ; Diagnsis active: atresia and stensis f arta using atresia and stensis f arta cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin nt dne: medical reasn using medical reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: patient reasn fr ACE inhibitr r ARB decline using patient reasn fr ACE inhibitr r ARB decline cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: patient reasn using patient reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: system reasn using system reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: anti platelet therapy ; Summary Calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria. The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr.

Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately. Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET 2011 2012